title: Patient experience and satisfaction with Onabotulinumtoxin A for refractory overactive bladder.
abstract: OBJECTIVE
  To evaluate the patient experience of our dedicated botulinum toxin A (BTX-A) service using a validated patient-reported experience measure (PREM) and assess patient-reported satisfaction with treatment.
  
  
  METHODS
  The first 100 patients who underwent BTX-A treatment for refractory idiopathic detrusor overactivity (IDO) in our institution were contacted for telephone interview. They had all been assessed, injected and followed up in a dedicated BTX-A clinic. Patients were asked to complete a validated PREM - the Client Satisfaction Questionnaire (CSQ-8) - as well as a questionnaire developed in our department to assess satisfaction with the results of the treatment. Most patients received 200 U OnabotulinumtoxinA (Botox(®) ) via an outpatient local anaesthetic flexible cystoscopy technique.
  
  
  RESULTS
  Complete data was available for 72 patients. In all, 49 patients were continuing to receive BTX-A treatment while 23 had opted for no further injections. The overall mean (sd) CSQ-8 satisfaction score was 38.3 (3.3), indicating a high level of patient satisfaction with the service offered in our institution. There was a significant difference in total satisfaction scores between those still receiving BTX-A (mean score 29.8) and those who have discontinued treatment (mean score 25.1) (P < 0.01). Overall patient satisfaction with the result of the treatment was high with an overall mean (sd) score of 8.6 (2.0) on a visual analogue scale. Of those who had discontinued BTX-A, most were either using conservative measures only (44%) or had recommenced anticholinergic medications.
  
  
  CONCLUSIONS
  Overall patient satisfaction with the dedicated BTX-A service offered in our institution is high and can result in a positive patient experience. The use of PREMs are advocated in order to fully capture the patient's views of the quality of services and treatments they receive.
authors.affiliation: Department of Urology, Guy's and St Thomas' NHS Foundation Trust, King's Health Partners, London, UK.
authors.forename: Sachin
authors.initials: S
authors.lastname: Malde
authors.affiliation: Department of Urology, Guy's and St Thomas' NHS Foundation Trust, King's Health Partners, London, UK.
authors.forename: Christopher
authors.initials: C
authors.lastname: Dowson
authors.affiliation: Department of Urology, Guy's and St Thomas' NHS Foundation Trust, King's Health Partners, London, UK.
authors.forename: Olivia
authors.initials: O
authors.lastname: Fraser
authors.affiliation: Department of Urology, Guy's and St Thomas' NHS Foundation Trust, King's Health Partners, London, UK.
authors.forename: Jane
authors.initials: J
authors.lastname: Watkins
authors.affiliation: Department of Urology, Guy's and St Thomas' NHS Foundation Trust, King's Health Partners, London, UK.
authors.forename: Muhammed S
authors.initials: MS
authors.lastname: Khan
authors.affiliation: Department of Urology, Guy's and St Thomas' NHS Foundation Trust, King's Health Partners, London, UK.
authors.forename: Prokar
authors.initials: P
authors.lastname: Dasgupta
authors.affiliation: Department of Urology, Guy's and St Thomas' NHS Foundation Trust, King's Health Partners, London, UK.
authors.forename: Arun
authors.initials: A
authors.lastname: Sahai
mesh_terms: D000328:Adult; D000368:Aged; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009465:Neuromuscular Agents / Q000627:therapeutic use*; D017060:Patient Satisfaction / Q000706:statistics & numerical data*; D012189:Retrospective Studies; D011795:Surveys and Questionnaires; D053201:Urinary Bladder, Overactive / Q000188:drug therapy* / Q000453:epidemiology; D055815:Young Adult
chemical_list: D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A
keywords: botulinum toxin A; overactive bladder; patient satisfaction; patient-reported experience measures